Maximal safe surgical resection followed by treatment with radiation and temozolomide (TMZ), with or without tumor treatment fields is the current yet inadequate standard of care.1,2 However, the benefit from TMZ in patients with O6-methylguanine-DNA methyltransferase (MGMT) unmethylated GBM (uGBM) is limited,3–5 and the omission of TMZ in patients with newly diagnosed uGBM in clinical trials is commonly considered acceptable if novel agents are tested in this patient population en lieu of TMZ.6,7. This evidence concerns the gene MGMT and neoplasm.